The FDA has approved UCB’s Kygevvi for treating children and adults with thymidine kinase 2 deficiency, an inherited mitochondrial disorder. It’s the drugmaker’s first ultra-rare disease product.
Epilepsy is a small part of UCB’s neurology pipeline, but its proposed Zogenix acquisition would broaden the Belgium-based drugmaker's ability to address that market. Zogenix’s Fintepla is approved in the U.S. and Europe for a rare type of epilepsy called Dravet syndrome, and is in development for other rare epilepsies.
How can AI benefit and improve patient outcome in the emergency department? Watch the latest episode to find out.
Maybe the FDA put a hidden meaning in the name of the new pain drug that everyone is worried about. When I hear “Zohydro,” I think of a boss that my son has to beat on a video game. Then I think of the multi-headed snake hydra. I did a quick search of hydra on […]
UnitedHealth Group Inc., one of the nation's largest health insurers, predicts that a majority of Americans could have diabetes or pre-diabetes by 2020, at a cost of $3.35 trillion to the health care system over the next 10 years, reports the Minneapolis/St. Paul Business Journal.
Though presumptive House Speaker John Boehner (R-Ohio) says of health reform, "there's a lot of tricks up our sleeves in terms of how we can dent this, kick it, slow it down to make sure it never happens," it is likely the law will remain intact in a divided Congress, according to the Washington Post.
Zogenix Inc. is attempting to raise $90 million through an initial public offering. The San Diego, California-based company said in a Securities & Exchange Commission filing it plans use the new money to commercialize its Sumavel DosePro drug-delivery device and advance its ZX002 pain drug in the clinic.
In a recent interview, Esperion president and CEO, Sheldon Koenig talks about the reality of statin intolerance and his company’s expansion into new diseases